Latest News

New Drugs Getting FDA's Blessing Faster, but Is That a Good Thing?


The result is that patients are being prescribed pricey new medications that have not been tested as rigorously, said lead researcher Jonathan Darrow, an assistant professor at Harvard Medical School.

Source link

Related posts

STAT Plus: To lower drug costs, CMS wants Medicare Part D plans to loosen formularies


Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: A systematic review and cost-effectiveness analysis


Health Tip: Hearing Loss Prevention


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy